Showing posts with label Blocking. Show all posts
Showing posts with label Blocking. Show all posts

Thursday, 5 September 2013

Procurement strategy is blocking NHS value for money

X-ray showing a hip replacement A single NHS contract to supply orthopaedic hip and knee replacements would save money and secure quality. Photograph: Rex Features

If we pooled all of the expertise within the NHS, we would have one of the best-equipped and most capable procurement teams in the world. It would hold all the cards to find cost savings while improving services for patients. The problem is that we don't pool expertise.

The government's NHS procurement strategy is dividing rather than uniting us. Bringing competition into the healthcare market is considered vital to ensure services are delivered a high standard. But, in many situations, this is contrary to procurement best practice, where pooling resources, knowledge and buying power delivers real savings.

NHS procurement needs more than a makeover. It requires fundamental changes in attitude to cope with the conflicting priorities of competition and collaboration.

The entire clinical strategy is geared up to seek best value services in a competitive market, but the national procurement strategy says we should be collaborating. Why should trusts seek to collaborate with each other when they are increasingly in competition on the provision of health services?

It is common knowledge that the competitiveness of your supply chain has a direct impact on the competitiveness of your products and services. That relates both to price and quality.

Try applying that logic to the health sector: as trusts, we're expected to share price information in order to drive best value, but that's tantamount to putting our competitive information directly into the hands of our rivals. And yet we should be seeking to consolidate nationally price and quality from suppliers. Take orthopaedics as an example. One national hip and knee contract for the whole of the NHS, rather than an undulating standard of price and quality, would hardly be a revolutionary idea. But it's sadly lacking today.

We should be pooling information and working together to drive best value and standardised quality through supplier contracts. This would give the entire NHS a quality baseline in terms of the services they deliver. Competition then comes into the equation in terms of service and specialisation in different trusts, but not in terms of price and not at the cost of squandering quality standards.

My personal approach to NHS procurement would be to split the strategy on an 80:20 basis between single national contracts and areas that remain open to competition.

Where the priority is best value and standardised quality, and in areas of little impact to health provision such as utilities, catering and office supplies, we should seek to collaborate on the widest scale possible. This would probably represent 20% of all NHS expenditure. The other 80% of spend, perhaps where local supply or specific products and services are priorities and there is less opportunity for consolidation, could remain competitive. As soon as the concept has been proven, inroads could then begin on the remaining 80%.

One challenge lies at the heart of the NHS procurement issue: a lack of joined-up information. Because we're all using different systems and processes for managing procurement and spending, there is no single picture of what the healthcare sector spends.

Until the NHS as a whole has a level of visibility through its systems and software it will be difficult to build a strategy that delivers simply because could be founded on inaccurate information. As a sector, we need a change of culture to affect a strategy led first by quality standards and second by selective competition. Until that happens, the NHS procurement makeover will prove little more than skin deep.

Malcolm Preston is associate director of procurement at County Durham and Darlington NHS Foundation Trust.

This article is published by Guardian Professional. Join the Healthcare Professionals Network to receive regular emails and exclusive offers.


View the original article here

Thursday, 1 August 2013

Orphan-drug designation for Nav1.7 blocking pain drug CNV1014802 granted

Main Category: Pain / Anesthetics
Also Included In: Regulatory Affairs / Drug Approvals
Article Date: 31 Jul 2013 - 0:00 PDT Current ratings for:
Orphan-drug designation for Nav1.7 blocking pain drug CNV1014802 granted
not yet ratednot yet rated

Convergence Pharmaceuticals Limited, is pleased to announce that its novel sodium channel blocker, CNV1014802 ('802), has been granted orphan-drug designation* by the US Food and Drug Administration for the treatment of trigeminal neuralgia (TN).

TN is a very severe form of facial pain that is experienced in short bursts or attacks called paroxysms. The International Association for the Study of Pain (IASP) defines TN as sudden, severe, brief, stabbing, recurrent episodes of pain usually on one side of the face and can be provoked by light touch. The pain follows one or more branches of the trigeminal nerve which provides nerve sensation from the mouth, face and the front of the scalp.

'802 is a novel small molecule that penetrates the central nervous system (CNS) and blocks Navs in a highly state-dependent fashion, while exhibiting selectivity against the 1.7 subtype. '802 is currently undergoing clinical evaluation in an innovative Phase II trial. An interim analysis from the trial reported in March that 70% of patients showed a successful response and were subsequently randomised into the double-blind treatment period. '802 was safe and well tolerated in these patients.

Clive Dix, Chief Executive Officer of Convergence Pharmaceuticals, commented: "This is a highly significant milestone for Convergence coming fast on the heels of positive interim data for '802. Trigeminal neuralgia is a highly debilitating disorder and current pain treatments come with a severe cost to quality of life. Orphan-drug designation will further smooth the path for the successful development of this novel sodium blocker and offer market exclusivity in the US if approved."

About Trigeminal Neuralgia (TN)

TN currently affects approximately 50,000 people in the USA alone. The majority of people affected are over 50 years of age; however, many cases have been reported in young adults. TN is more prevalent in women than men, and for most sufferers, the condition is progressive and worsens over time. TN is commonly misdiagnosed and to date there is no guaranteed cure for the condition. Current therapies are centred on sodium channel blockers such as carbamazepine or oxcarbazepine as first-line treatments. However, these agents, although providing relief, are often poorly tolerated, and require lengthy dose escalation, resulting in sub-optimal efficacy.

About chronic pain

Currently, more than 1.5 billion people worldwide suffer from chronic pain of varying degrees. Among all types of chronic pain, neuropathic pain stands out with approximately 3-4.5% of the global population affected, with incidence rate increasing in line with increased age of the population. With the unmet clinical need so high, the demand for better pain management therapies, addressing acute and chronic pain, is on the rise.

According to recent research the global pain management market is to reach US$60 Billion by 2015.[1]

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our pain / anesthetics section for the latest news on this subject.

* Orphan-drug designation gives Convergence various incentives and advantages in the development of '802, including the potential availability of certain grants for clinical studies and assistance from the FDA with clinical protocol design. Furthermore orphan drug designation grants US market exclusivity, distinct from other types of exclusivity, for seven years if '802 is approved.

1) Global Industry Analysts Inc. 2010, "Pain Management: A Global Strategic Business Report".

Convergence Pharmaceuticals

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Pharmaceuticals, Convergence. "Orphan-drug designation for Nav1.7 blocking pain drug CNV1014802 granted." Medical News Today. MediLexicon, Intl., 31 Jul. 2013. Web.
31 Jul. 2013. APA

Please note: If no author information is provided, the source is cited instead.


'Orphan-drug designation for Nav1.7 blocking pain drug CNV1014802 granted'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam). We reserve the right to amend opinions where we deem necessary.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Tuesday, 30 July 2013

Blocking a master switch controlling cells' response to low levels of oxygen could lead to new cancer drugs

Main Category: Cancer / Oncology
Article Date: 29 Jul 2013 - 1:00 PDT Current ratings for:
Blocking a master switch controlling cells' response to low levels of oxygen could lead to new cancer drugs
not yet ratednot yet rated

Scientists have discovered a new molecule that prevents cancer cells from responding and surviving when starved of oxygen and which could be developed into new treatments for the disease, according to new research published in the Journal of the American Chemical Society.

Cancer Research UK scientists at the University of Southampton found that this molecule targets the master switch -- HIF-1 -- that cancer cells use to adapt to low oxygen levels, a common feature in the disease.

The researchers uncovered a way to stop cancer cells using this switch through an approach called 'synthetic biology'. By testing 3.2 million potential compounds, made by specially engineered bacteria, they were able to find a molecule that stopped HIF-1 from working.

All cells need a blood supply to provide them with the oxygen and nutrients they require to survive. Cancer tumours grow rapidly and as the tumour gets bigger it outstrips the supply of oxygen and nutrients that the surrounding blood vessels can deliver.

But, to cope with this low-oxygen environment, HIF-1 acts as a master switch that turns on hundreds of genes, allowing cancer cells to survive. HIF-1 triggers the formation of new blood vessels around tumours, causing more oxygen and nutrients to be delivered to the starving tumour, which in turn allows it to keep growing.

Dr Ali Tavassoli, a Cancer Research UK scientist whose team discovered and developed the compound at the University of Southampton, said: "We've found a way to target the steps that cancer cells take to survive and we hope that our research will one day lead to effective drugs that can stop cancers adapting to a low oxygen environment, stopping their growth. The next step is to further develop this molecule to create an effective treatment."

Dr Julie Sharp, senior science information manager at Cancer Research UK, said: "Finding ways to disrupt the tools that cancer cells use to adapt and grow when starved of oxygen has been a hot topic in cancer research, but finding drugs that do this effectively has proved elusive.

"For the first time our scientists have found a way to block a master switch controlling cells response to low levels of oxygen -- an important step towards creating drugs that could halt cancer in its tracks."

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our cancer / oncology section for the latest news on this subject. Please use one of the following formats to cite this article in your essay, paper or report:

MLA

University of Southampton. "Blocking a master switch controlling cells' response to low levels of oxygen could lead to new cancer drugs." Medical News Today. MediLexicon, Intl., 29 Jul. 2013. Web.
29 Jul. 2013. APA

Please note: If no author information is provided, the source is cited instead.


'Blocking a master switch controlling cells' response to low levels of oxygen could lead to new cancer drugs'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam). We reserve the right to amend opinions where we deem necessary.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here